Article Information
History
- May 26, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Andrew H. Karaba, MD, PhD1,*,
- Jake D. Kim, BA2,*,
- Teresa P-Y Chiang, MD, MPH2,
- Jennifer L. Alejo, MD2,
- Aura T. Abedon, BS2,
- Jonathan Mitchell, MBBS2,
- Amy Chang, MD2,
- Yolanda Eby, MS3,
- Trevor Scott Johnston, BS1,
- Tihitina Aytenfisu, BA1,
- Casey Hussey, MS3,
- Alexa Jefferis, BS2,
- Nicole Fortune, BS2,
- Rivka Abedon2,
- Letitia Thomas2,
- Daniel S. Warren, PhD2,
- Ioannis Sitaras, PhD4,
- Andrew Pekosz, PhD4,
- Robin K. Avery, MD1,
- Allan B. Massie, PhD, MHS2,5,6,
- William A. Clarke, MD3,
- Aaron A.R. Tobian, MD, PhD3,
- Dorry L. Segev, MD, PhD2,5,6 and
- William A. Werbel, MD1,*
- 1Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore MD
- 2Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore MD
- 3Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
- 4Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
- 5Department of Surgery, NYU Grossman School of Medicine, New York, NY
- 6Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD
- ↵#Contact Information: William A. Werbel, M.D., Assistant Professor, Department of Medicine, 2000 E. Monument St, Baltimore, MD 21205, Tel: 410-614-0648, wwerbel1{at}jhmi.edu
↵* AHK and JDK contributed equally
Posted May 26, 2022.
Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients
